+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Impact of Triiodothyronine on the Survival of High-Risk Patients Undergoing Open Heart Surgery

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Experimental and clinical studies have shown the beneficial effects of triiodothyronine (T<sub>3</sub>) following myocardial revascularization on cardiopulmonary bypass (CPB). In this study, open-label T<sub>3</sub> was administered to 68 high-risk patients undergoing open heart surgery. The New Jersey Risk Assessment was used to calculate the preoperative estimated surgical mortality. A loading dose of T<sub>3</sub> was administered: (a) at release of the aortic cross-clamp, (b) whenever the patient became CPB dependent, (c) if the patient exhibited low cardiac output after discontinuing CPB and (d) as pretreatment before initiating CPB. All therapeutic modalities were followed by a continuous T<sub>3</sub> infusion. Following T<sub>3</sub> therapy, CPB was discontinued in all patients. Based upon discriminant analysis, a total of 26 deaths were expected from the entire group, but only 7 patients died, therefore, the observed mortality was reduced by 72% (p < 0.007). The use of T<sub>3</sub> had a major impact on reducing surgical mortality, and may be advocated as a new therapeutic modality in patients with high estimated mortality undergoing open heart surgery.

          Related collections

          Author and article information

          S. Karger AG
          19 November 2008
          : 87
          : 6
          : 509-515
          aDepartment of Surgery, bDivision of Cardiology and cDepartment of Anesthesia, University of South Florida, Tampa, Fla., dPharmacy Services, James A. Haley VA Hospital, Tampa, Fla., eDepartment of Surgery, Newark Beth Israel Medical Center, Newark, N.J., USA
          177147 Cardiology 1996;87:509–515
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Cardiac Surgery


          Comment on this article